(NASDAQ: DARE) Dare Bioscience's forecast annual revenue growth rate of 191.77% is forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 30.21%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.47%.
Dare Bioscience's revenue in 2026 is $1,365,939.On average, 5 Wall Street analysts forecast DARE's revenue for 2026 to be $42,382,500, with the lowest DARE revenue forecast at $5,094,462, and the highest DARE revenue forecast at $114,671,265. On average, 4 Wall Street analysts forecast DARE's revenue for 2027 to be $138,232,388, with the lowest DARE revenue forecast at $80,346,333, and the highest DARE revenue forecast at $198,503,604.
In 2028, DARE is forecast to generate $578,019,623 in revenue, with the lowest revenue forecast at $433,258,618 and the highest revenue forecast at $725,838,528.